Výsledky vyhledávání - "Anthony Hee Kong"

Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232)

Autor: Tamara Rordorf, Anthony Hee Kong, Jason Chesney, Jenny J. Kim, Jesus Corral Jaime, Vittoria Espeli, Burak Gumuscu, Kevin J. Harrington, Nicolas Mach, Sheryl Treichel

Publikováno v: Journal of Clinical Oncology. 36:6036-6036

6036Background: We evaluated the safety and efficacy of the combo of T-VEC, the first FDA-approved oncolytic immunotherapy that enhances systemic antitumor immune responses, and Pembro, an immune c...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::005d1298798973f6e0b4118835556c3b
https://doi.org/10.1200/jco.2018.36.15_suppl.6036

Zobrazit plný text záznamu

EORTC 1559-HNCG: A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)—'UPSTREAM'

Autor: Christophe Le Tourneau, Esma Saada-Bouzid, Catherine Fortpied, Carmela Caballero, Lisa Licitra, Jean-François Laes, Joël Guigay, Jean-Pascal Machiels, Jean-Luc Re Canon, Stéphanie Henry, Rachel Galot, Anne-Sophie Govaerts, Anthony Hee Kong, Tiana Raveloarivahy, Dominiek Staelens, Inge Tinhofer

Publikováno v: Journal of Clinical Oncology. 36:TPS6095-TPS6095

TPS6095Background: The treatment of R/M SCCHN includes platinum-based chemotherapy, cetuximab, and anti-PD-1 compounds. Some genetic alterations have been identified, making SCCHN attractive for mo...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a0677c08814cd297c228d93d3304572e
https://doi.org/10.1200/jco.2018.36.15_suppl.tps6095

Zobrazit plný text záznamu

Phase III randomised controlled trial (RCT) comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer (CompARE)

Publikováno v: Journal of Clinical Oncology. 35:TPS6091-TPS6091

TPS6091 Background: Patients with intermediate and high-risk oropharyngeal cancer (OPC) have poorer response to standard treatment and poorer overall survival compared to low-risk OPC. The CompARE trial is designed to test alternative approaches to i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4116df89cbbf199011df9a197bfe448d
https://doi.org/10.1200/jco.2017.35.15_suppl.tps6091

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání